Capsul Desk

Capsul Desk writes each daily edition. We are senior reporters and editors from Norstella's News and Insights division, with decades covering the industry's full arc, from a molecule's first trial to the pricing fight that decides who can afford it.

Page 1 of 3

People climbing an outdoor staircase in single file, seen from behind and below against a bright, washed-out sky.

Milestone Monday: In This IPO Market, $81m Is The Small One

Aug 17, 2026 Capsul Desk 4 min read members

The Long View: Sanofi Rebuilds Its Workforce Around AI, Just As It Gets Pickier About What Advances

The discovery engine now runs twice as fast. A new chief executive is culling late-stage assets and raising the Phase II bar, so the bet rides on whether faster also means better.

Aug 14, 2026 Capsul Desk 6 min read members

A sprinter crouched in the starting blocks on a red running track, one hand holding a relay baton behind the white start line, poised to push off.

Trial Tuesday: The Number Arrowhead Wasn't Looking For

Twin trials erased acute pancreatitis in high-risk patients, and Arrowhead priced its drug just above Ionis's, not below. The full readout lands at ESC on Aug 30, where analysts settle the score.

Aug 11, 2026 Capsul Desk 4 min read members

A person stands at the foot of a dark staircase; light hits the bottom and top steps but not the middle.

Milestone Monday: In Biopharma Venture Funding, The Middle Round Goes Missing

Three nine-figure private raises and a royalty deal worth up to $425m in a two-week run last month, with almost nothing in the $50m to $100m band between them and the seed stage. The companies that need that rung are learning to route around it.

Aug 10, 2026 Capsul Desk 4 min read members

A masked clinician in green scrubs and goggles works at a hospital workstation lined with monitors showing medical scans.

The Long View: Where Medical AI Leaves The Lab For The Clinic

The research exemptions written into the AI Act, amended in July, were meant to protect science. A KU Leuven and Stanford paper warns they may also be the easiest place to hide, and that even honest researchers may not be able to tell whether their work counts as research or something more.

Aug 7, 2026 Capsul Desk 6 min read members

Low-angle view of several glass office towers converging toward a cloudy sky.

Milestone Monday: A $400bn Question, And The Deals That Actually Got Signed

Bristol Myers and AstraZeneca are reported to be talking. While that plays out, argenx, J&J and Caldera each put real money behind a thesis last week.

Aug 3, 2026 Capsul Desk 5 min read members

A man in a grey suit, seen from behind, walks alone across an open plaza carrying a green holdall, past a large red-panelled wall streaked with diagonal shadows.

The Long View: Pharma Is Walking Out On Gene Therapy. Dyno Is Walking In.

The names with the most money in AAV are leaving. Eric Kelsic's bet is that they left too early, and he's licensing the tools to argue that first-generation capsids and broken economics, not the vector, emptied the field.

Jul 31, 2026 Capsul Desk 6 min read members

Rows of antique clocks, each set to a different time

Milestone Monday: The Biotech Clocks Running Into 2027

Aphaia's obesity data leads the pack, Connect's acute-asthma topline lands in September, Kyverna's CAR-T filing by year end. What each result decides, and who's waiting to write the check.

Jul 27, 2026 Capsul Desk 5 min read members

Cyclist crossing a long arched bridge over water in fog, black and white.

The Long View: A Generic You Forgot About Can Derail Your Trial

Carboplatin and cisplatin sit in the comparator arms of the oncology studies meant to replace them. ASCO's chief medical officer says a missing generic can halt a trial and delay the approval behind it.

Jul 24, 2026 Capsul Desk 6 min read members

An empty forest road climbing toward misty light, one vehicle partway up.

Therapeutic Thursday: A Fringe RNA Drug Is Now First Of Its Kind In The Clinic

Today is a quiet kind of vindication story, the sort the industry doesn't hand out often. A founder spent 15 years insisting that the junk stretches of the

Jul 23, 2026 Capsul Desk 4 min read members

People in a single-file line along a gray wall, all looking at their phones.

Milestone Monday: Thirteen Biotech IPOs In 2026, And Five More Just Got In Line

Jul 20, 2026 Capsul Desk 4 min read members

Interior of an early-20th-century pharmacy, walls lined with labeled dispensing bottles and glass display cabinets.

The Long View: Pharma Is Paying More For Less-Proven Science

Jul 17, 2026 Capsul Desk 5 min read members